Anlon Healthcare Quarterly Results for Trading Insights
In Mar 2026, Anlon Healthcare (AHCL) reported revenue ₹51 Cr and net profit ₹11 Cr — revenue +4.1% YoY. Also explore Anlon Healthcare share price performance to track price trends across different timeframes.
AHCL Quarterly Results — Revenue, Profit & EPS Highlights
Anlon Healthcare latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse AHCL financial statements for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹51 Cr in Mar 2026 (-42.0% vs Jun 2026, +4.1% vs Mar 2025)
- Net Profit of ₹11 Cr in Mar 2026 (+37.5% vs Jun 2026, -35.3% vs Mar 2025)
- EBITDA of ₹15 Cr in Mar 2026 (-6.2% vs Jun 2026)
- Operating Margin of 30.0% in Mar 2026 (+12.0pp vs Jun 2026)
- Earnings Per Share of ₹2.33 in Mar 2026 (+1356.2% vs Jun 2026)
Anlon Healthcare Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AHCL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 51 | 88 | 52 | 49 | 33 | -42.0% | 4.1% |
| Net Profit (₹ Cr) | 11 | 8 | 9 | 17 | 4 | - | - |
| EBITDA (₹ Cr) | 15 | 16 | 14 | 17 | 6 | - | - |
| EPS (₹) | 2.33 | 0.16 | 1.75 | 5.15 | 0.89 | - | - |
| Operating Margin (%) | 30.0% | 18.0% | 26.0% | 35.0% | 19.0% | - | - |
AHCL Share Price Trend — 1-Year Movement Across Quarterly Results
Anlon Healthcare 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Anlon Healthcare share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AHCL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Anlon Healthcare latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores